Division of Diagnostic and Therapeutic Neuroradiology, St. Michael's Hospital, Toronto, Ontario, Canada.
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Neurosurgery. 2018 Dec 1;83(6):1298-1305. doi: 10.1093/neuros/nyx628.
Flow diversion for basilar apex aneurysms has rarely been reported.
To assess flow diversion for basilar apex aneurysms in a multicenter cohort.
Retrospective review of prospectively maintained databases at 8 academic institutions was performed from 2009 to 2016 to identify patients with basilar apex aneurysms treated with flow diversion. Clinical and radiographic data were analyzed.
Sixteen consecutive patients (median age 54.5 yr) underwent 18 procedures to treat 16 basilar apex aneurysms with either the Pipeline Embolization Device (Medtronic Inc, Dublin, Ireland) or Flow Redirection Endoluminal Device (Microvention, Tustin, California). Five aneurysms (31.3%) were treated in the setting of subarachnoid hemorrhage. Seven aneurysms (43.8%) were treated with flow diversion alone, while 9 (56.2%) underwent flow diversion and adjunctive coiling. At a median follow-up of 6 mo, complete (100%) and near-complete (90%-99%) occlusion was noted in 11 (68.8%) aneurysms. Incomplete occlusion occurred more commonly in patients treated with flow diversion alone compared to those with adjunctive coiling. Patients with partial occlusion were significantly younger. Retreatment with an additional flow diverter and adjunctive coiling occurred in 2 aneurysms with wide necks. There was 1 mortality in a patient (6.3%) who experienced posterior cerebral artery and cerebellar strokes as well as subarachnoid hemorrhage after the placement of a flow diverter. Minor complications occurred in 2 patients (12.5%).
Flow diversion for the treatment of basilar apex aneurysms results in acceptable occlusion rates in highly selected cases. Both primary flow diversion and rescue after failed clipping or coiling resulted in a modified Rankin Scale score that was either equal or better than at presentation and the technology represents a viable alternative or adjunctive option.
基底动脉尖动脉瘤的血流导向治疗鲜有报道。
评估多中心队列中基底动脉尖动脉瘤的血流导向治疗效果。
对 2009 年至 2016 年 8 所学术机构前瞻性维护的数据库进行回顾性分析,以确定接受血流导向治疗的基底动脉尖动脉瘤患者。分析临床和影像学资料。
16 例连续患者(中位年龄 54.5 岁)接受了 18 次手术,使用 Pipeline 栓塞装置(美敦力公司,都柏林,爱尔兰)或 Flow Redirection 腔内装置(Microvention,加利福尼亚州图森市)治疗 16 个基底动脉尖动脉瘤。其中 5 个动脉瘤(31.3%)在蛛网膜下腔出血时进行治疗。单纯血流导向治疗 7 例(43.8%),单纯血流导向治疗加辅助弹簧圈栓塞 9 例(56.2%)。中位随访 6 个月时,11 个动脉瘤(68.8%)完全(100%)或近完全(90%-99%)闭塞,单纯血流导向治疗组不完全闭塞的发生率明显高于辅助弹簧圈栓塞组。部分闭塞的患者更年轻。2 个瘤颈较宽的动脉瘤采用附加血流导向装置和辅助弹簧圈进行了再治疗。1 例患者(6.3%)死亡,该患者在放置血流导向装置后出现大脑后动脉和小脑卒中和蛛网膜下腔出血。2 例患者(12.5%)出现轻微并发症。
对于高度选择的病例,血流导向治疗基底动脉尖动脉瘤可获得可接受的闭塞率。原发性血流导向治疗和失败的夹闭或弹簧圈治疗后的挽救治疗均使改良 Rankin 量表评分与发病时相同或更好,该技术是一种可行的替代或辅助治疗选择。